Papyriflavonol A, a new prenylated flavonol isolated from Broussonetia papyrifera, selectively inhibits recombinant human secretory phospholipase A 2 s (sPLA 2 s). Papyriflavonol A was found to inhibit human group IIA and V sPLA 2 s potently and irreversibly in a dose-dependent manner, with respective IC 50 values of 3.9 and 4.5 m mM. The inhibitory effects of papyriflavonol A against bovine group IB (IC 50 of 76.9 m mM) and the human group X (IC 50 of 225 m mM) sPLA 2 s were weaker than those against human group IIA and V sPLA 2 s, and human group IIF sPLA 2 was not inhibited. In addition, papyriflavonol A potently inhibited the stimulus-induced production of leukotriene C 4 with an IC 50 value of approximately 0.64 m mM in mouse bone marrow-derived mast cells. In addition, papyriflavonol A significantly reduced IgE-dependent passive cutaneous anaphylaxis in rats. These results indicate that papyriflavonol A provides a basis for novel types of antiinflammatory drugs.
Phospholipase A 2 (PLA 2 ) is a growing family of distinct enzymes that exhibits different substrate specificities, cofactor requirements, subcellular localization, and cellular functions.
1) Secretory PLA 2 s (sPLA 2 s) have low molecular weights (14-18 kDa) with a rigid tertiary structure configured by 6-8 disulfide bridges. They require millimolar concentrations of Ca 2ϩ to exert their enzymatic action and have little fatty acid selectivity when assayed in vitro.
2) Thus far, 10 genes coding for structurally related and enzymatically active sPLA 2 s have been identified in mammals (groups IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XII). [3] [4] [5] [6] [7] Group IB sPLA 2 (sPLA 2 -IB), known as pancreatic PLA 2 , is abundant in the pancreatic juice, where it catalyzes the breakdown of dietary phospholipids. Group IIA sPLA 2 (sPLA 2 -IIA), known as an inflammatory PLA 2 , is expressed in a variety of tissues and is markedly induced following challenge with proinflammatory stimuli [8] [9] [10] sPLA 2 -IIA is thought to play a role in inflammation, 8, 11, 12) exocytosis, 13, 14) blood coagulation, 15) and atherosclerosis. 16, 17) sPLA 2 -IIA involvement in the inflammatory process has also been investigated by the administration of particular inhibitors or antibodies that are fairly specific to sPLA 2 -IIA into inflamed sites. For example, injecting a monoclonal antibody that neutralizes sPLA 2 -IIA activity into rats with carrageenan-induced pleurisy reduced the pleural exudate volume and the intrapleural leukocyte number significantly.
18) Group V sPLA 2 (sPLA 2 -V) is expressed mainly in rats and the human heart 19) and various mouse tissues. 20) This enzyme may compensate for sPLA 2 -IIA under certain conditions since it is induced in many tissues by proinflammatory agents 20, 21) in a similar manner as sPLA 2 -IIA. [8] [9] [10] sPLA 2 -IIA and -V, the genes for which are clustered on the same chromosome locus, share several enzymatic and functional features. 22, 23) These enzymes are therefore referred to as the group II subfamily of sPLA 2 , into which several novel sPLA 2 enzymes, including group IIC, IID, IIE and IIF, are also classified. [3] [4] [5] [6] Group X sPLA 2 (sPLA 2 -X) is constitutively expressed in the immune and digestive organs. 24) Current cellular biological evidence suggests that sPLA 2 -IIA, -IID, -V, and -X are capable of promoting cellular arachidonate release. 9, 10, [20] [21] [22] [23] 25, 26) This fact, together with the observation that sPLA 2 s belongs to the group II subfamily (IIA, IID, IIE, and V) are stimulus inducible, 3, 6, [8] [9] [10] 20, 21) implies the possible involvement of these enzymes in the inflammatory process. If this is the case, one might anticipate that the inhibition of the inducible group II subfamily of sPLA 2 s can attenuate the severity of inflammation.
Prenylated flavonoids have a limited distribution in the plant kingdom, i.e., the Moraceae. Most of these plants have various types of prenylated flavonoids as major constituents and have been used as antiinflammatory agents from antiquity. 27) These molecules have the chemical constituents with an isoprenyl (3,3-dimethylallyl), geranyl (E-3,7-dimethyl-2,6-octadienyl), 1,1-dimethylallyl, and/or lavandulyl (5-methyl-2-isoprophenyl-hex-4-enyl) moiety added to their flavonoid backbone structure. 28) During investigations of the effects of various flavonoid derivatives on sPLA 2 s, papyriflavonol A isolated from Broussonetia papyrifera was found to inhibit sPLA 2 -IIA and -V more potently than other sPLA 2 enzymes. The inactivation patterns of various mammalian sPLA 2 s in vitro by this new prenylated flavonoid and its antiinflammatory activity in vivo were also examined.
MATERIALS AND METHODS

Enzyme Sources
The cDNAs for human sPLA 2 -IIA, -V, and -X were cloned into an expression vector and transfected Assay of Phospholipase A 2 Inhibitory Activity by Papyriflavonol A The standard reaction mixture (200 ml) contained 100 mM Tris-HCl (pH 9.0), 6 mM CaCl 2 , 1% bovine serum albumin, 2.5 mM of radiolabeled 1-acyl-2-[1-
14 C] arachidonoyl-sn-glycerol phosphoethanolamine (48 mCi/m mole, NEN, Boston, MA, U.S.A.), and papyriflavonol A. The reaction was started by the addition of an aliquot of the culture medium as an enzyme source and carried out at 37°C for 20 min, and [ 14 C] arachidonic acid released was extracted by the method described previously.
11) Under these conditions, the reaction mixture without papyriflavonol A released 10% free fatty acid. Inhibition was expressed as a percentage; with enzyme control as 100% reaction, i.e., 0% inhibition. Papyriflavonol A was dissolved in dimethylsulfoxide (DMSO) and added to the enzyme assay tubes at 2% of the final volume. Control experiments showed that DMSO at concentrations up to 2% had no effect on enzymatic activity. All data are expressed as the mean of duplicate determinations.
Preparation of Mouse Bone Marrow-Derived Mast Cells Bone marrow cells from male BALB/cJ mice were cultured for up to 10 weeks in 50% enriched medium (RPMI 1640 containing 100 units/ml penicillin, 100 mg/ml of streptomycin, 10 mg/ml of gentamycin, 2 mM of L-glutamine, 0.1 mM of nonessential amino acids, and 10% fetal calf serum) and a 50% WEHI-3 cell-conditioned medium as a source of interleukin-3. After 3 weeks, more than 98% of the cells in the culture were bone marrow-derived mast cells (BMMCs). [29] [30] [31] Determination of Leukotriene C 4 Leukotriene C 4 production was determined using an LTC 4 enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI, U.S.A.) according to the manufacturer's instructions. BMMC suspended in enriched medium at cell density of 1ϫ10 6 cells/ml were pretreated with papyriflavonol A for 30 min at 37°C and stimulated with stem cell factor (SCF; 100 ng/ml), which was recombinantly expressed by the baculovirus/insect cell expression system. [29] [30] [31] After 20-min stimulation, the supernatants were isolated for further analysis by enzyme immunoassay. Papyriflavonol A was solved in DMSO and added to the cells at 0.05% of the final volume.
Passive Cutaneous Anaphylaxis Male Sprague-Dawley rats weighing 180-200 g (Hyochang Science, Daegu, Korea) were used in the passive cutaneous anaphylaxis test. The animals were housed in cages at least 1 week before the experiments. In brief, 100 ml/site of monoclonal anti-DNP mouse IgE (1 : 1000 dilution; Seikagaku-Kougyo, Japan) was intradermally injected in the shaved back of the rat. After 48 h, PCA was evoked by intravenous injection of the antigen (Ag; 1 mg of DNP-BSA; Sigma Chemical, St. Louis, MO, U.S.A.) in phosphate-buffered saline (PBS) containing 1 ml of 1% Evans blue (1 : 4). Papyriflavonol A (12.5 to 50 mg/kg body weight, i.p.) was administered 10 h before Ag challenge.
After 30 min, the skin was removed and the dye leaking into the skin was extracted and quantified, as described previously.
32)
RESULTS
Papyriflavonol A Inhibits Basic Group II Subfamily sPLA 2 s in Vitro A comparative test was performed to determine how papyriflavonol A (Fig. 1) affects various mammalian sPLA 2 s. Figure 2 shows that papyriflavonol A inhibits recombinant human sPLA 2 -IIA and -V (IC 50 of ca. 3.9 and ca. 4.5 mM respectively) more potently than bovine pancreatic sPLA 2 -IB (IC 50 of ca. 76.9 mM). Inhibition of sPLA 2 -X was only partial and reached a plateau (as much as 40% inhibition) at a dose of more than 80 mM. Human sPLA 2 -IIF was not inhibited by papyriflavonol A even at 1 mM. Thus the inhibitory effect of papyriflavonol A was in the order of IIAՆVϾ ϾIBϾXϾIIF. This suggests that papyriflavonol A inhibits basic sPLA 2 s in preference to neutral and acidic sPLA 2 s.
Papyriflavonol A Inhibits LTC 4 Production by Mast Cells BMMCs stimulated for 15 min with SCF produced ca. 500 pg/ml of LTC 4 , and preincubation of cells with papyriflavonol A resulted in the dose-dependent suppression of LTC 4 biosynthesis with an IC 50 value of 0.65 mM and with almost complete inhibition at 7.2 mM (Fig. 3) . This particularly low IC 50 value may reflect the inhibition of two regulatory steps for LTC 4 biosynthesis, namely arachidonate release by sPLA 2 
-V and its conversion to LTs by 5-lipoxygenase (5-LO), by papyriflavonol A.
Papyriflavonol A Inhibits the PCA Reaction in Vivo To explore the antiinflammatory activity of papyriflavonol A in vivo, the effect of this compound on IgE-induced PCA was examined in a rat model (Fig. 4) . Papyriflavonol A showed 
DISCUSSION
Extracellular sPLA 2 -IIA activity has been detected in the inflamed sites of several experimental animal models, 11, 33, 34) and in human diseases such as pancreatitis and rheumatoid arthritis. [35] [36] [37] The correlation between sPLA 2 -IIA levels and disease status has led to the development of pharmacological agents that are capable of inhibiting sPLA 2 -IIA and possibly the activities of other sPLA 2 , which would be expected to be beneficial for the mitigation of disease. As a result of our ongoing efforts to develop new sPLA 2 inhibitors from natural products using an activity-guided isolation procedure, we isolated a new human sPLA 2 -IIA and -V inhibitor, papyriflavonol A, from B. papyrifera.
Although the primary structures of the sPLA 2 isozymes show some homology (30-50%), they contain two wellconserved regions comprising the "active site" and "the Ca 2ϩ -binding site." 2, 8) It is noteworthy that the IC 50 values of papyriflavonol A and of sPLA 2 -IIA and sPLA 2 -V are almost the same sPLA 2 -IIA and sPLA 2 -V exhibit redundant functions under certain conditions and their genes are clustered in the same chromosome locus, whereas sPLA 2 -IB and sPLA 2 -X are more distant.
2) sPLA 2 -IIF is unique (a region where basic amino acids are clustered; see below) among the group II subfamily of sPLA 2 s in that it is an acidic protein and has an unusually long C-terminal extension. 5) Papyriflavonol A may recognize the subtle structural differences between these enzymes and bind preferentially to a unique region present only in sPLA 2 -IIA and sPLA 2 -V, because it exhibits stronger inhibitory activity against sPLA 2 -IIA and -V than against sPLA 2 -IB, -X, and -IIF.
It is worth noting that papyriflavonol A can carry negative charges in neutral or alkaline solution because of the presence of multiple phenolic hydroxyl groups (Fig. 1) . Both sPLA 2 -IIA and -V are highly cationic proteins, whereas sPLA 2 -IB is neutral and both sPLA 2 -X and -IIF are acidic (the pI values for sPLA 2 -IIA, V, IB, X, and IIF were found to be 9.4, 8.7, 6.9, 5.1, and 4.7, respectively).
2) Several basic amino acids in human sPLA 2 -IIA (and probably in -V) are essential for its interfacial recognition, and therefore the attendant hydrolysis, of negatively charged substrates. 38, 39) It is therefore conceivable that papyriflavonol A binds preferentially to basic sPLA 2 s via a charge-based interaction, whereas it binds poorly to the charge-neutral sPLA 2 -IB and acidic sPLA 2 -X and -IIF.
Papyriflavonol A was recently reported to exert an inhibitory effect on 5-LO, but not the cyclooxygenases (COX), with an IC 50 of 7 mM (when homogenates of rat polymorphonuclear mononuclear cells were used as the enzyme source). 40) However, whether papyriflavonol A has an inhibitory effect on LT production at the cellular level, or whether it has antiinflammatory activity in vivo has not been reported. Therefore the effect of papyriflavonol A on LTC 4 generation in BMMCs was examined. This cell model appears to be suitable for assessing the effect of papyriflavonol A, since immediate LTC 4 generation elicited by IgE-dependent or cytokine-initiated stimulus occurs in BMMCs through the functional coupling between sPLA 2 -V in cooperation with cPLA 2 and 5-LO. 25, 41) As shown in Fig. 4 , the suppression of the IgE/anti-IgE-induced PCA reaction by papyriflavonol A is dose dependent, and an injection of 12.5 mg/kg of papyriflavonol A 10 h before Ag challenge significantly reduced this reaction. However, its in vivo dynamics and metabolism await future study. Our results suggest that sPLA 2 s may be involved in the PCA reaction by augmenting LTC 4 production by tissue mast cells (or other inflammatory cells), and that papyriflavonol A blocks that process. However, considering the general concept that the participation of COX or 5-LO products in the PCA reaction in the rat is relatively weak, we cannot rule out the possibility that papyriflavonol A can affect other sPLA 2 -regulatory processes, such as histamine release. We have previously shown that sPLAs (sPLA 2 -V in particular) have the ability to augment both histamine release and LTC 4 production by mast cells. 14) Although our preliminary data demonstrated that degranulation of BMMCs was suppressed only minimally by papyriflavonol A in vitro (data not shown), it is possible that degranulation of rat skin mast cells (connective tissue-type mast cells) is susceptible to sPLA 2 s (and is therefore suppressed by papyriflavonol A), since histamine release from connective tissue-type mast cells, but not from BMMCs, is markedly enhanced by lysophosphatidylserine, an sPLA 2 reaction product.
42) The more profound inhibitory effect of papyriflavonol A on LTC 4 production by mast cells than on in vitro sPLA 2 activity suggests that the inhibition of 5-LO activity by papyriflavonol A 40) also contributes to reduced LTC 4 production. Nonetheless, our present results provide a new insight into the role of sPLA 2 in acute allergic re- BMMCs were preincubated for 30 min with the indicated concentrations of papyriflavonol A and then stimulated with 100 ng/ml of control SCF for 15 min. LTC 4 released into the supernatant was quantified using an EIA kit. action and demonstrate the potential of papyriflavonol A to serve as a leading developmental compound for novel antiinflammatoty and antiallergic drugs.
